Stay updated with breaking news from Sureshk durgam. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Get Free Report) has received an average rating of “Moderate Buy” from the ten ratings firms that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 1-year target price among […] ....
Mach 1 Financial Group LLC bought a new position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The fund bought 7,180 shares of the biopharmaceutical company’s stock, valued at approximately $514,000. Several other hedge funds and other institutional investors […] ....
Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 36.1% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 18,738 shares of the biopharmaceutical company’s stock after acquiring an additional 4,974 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s […] ....
Intra-Cellular Therapies (NASDAQ:ITCI – Get Free Report) had its target price upped by Mizuho from $82.00 to $96.00 in a note issued to investors on Monday, Benzinga reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Mizuho’s price objective points to a potential upside of 29.71% from the stock’s previous close. […] ....
Intra-Cellular Therapies (NASDAQ:ITCI – Free Report) had its price objective boosted by Canaccord Genuity Group from $100.00 to $107.00 in a report released on Tuesday morning, Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock. Other research analysts have also issued research reports about the company. Robert W. Baird increased […] ....